Contents
Participation in medical research should be accessible to everyone. We can bridge the gap between health volunteers, organizations, and groundbreaking clinical research, right here in Connecticut.
Together, we can push boundaries, challenge the status quo, and drive progress where it matters most. Your participation has the power to transform lives.
Clinical Trials For Disease Areas in Connecticut
Connecticut is a hotspot for medical innovation. With renowned institutions, like Grove Hill Clinical Research, experts are leading the way in various fields. Our state excels in the study of a wide range of diseases.
Clinical research trials in Connecticut are committed to pioneering investigations on cancer research, neurological disorders, mental health, chronic disease treatment, microbiology, and more. These research strengths make it a key player in the field of medicine.
Recently, Connecticut experts explained that another experimental drug for Alzheimer’s can slow a patient’s memory decline by roughly 4 to 7 months. The drug donanemab is waiting for FDA approval. If cleared, it could be a promising treatment for the disease.
Here is a list of active and future trials that could offer valuable results.
Follow-up Visit of High Risk Infants
Recruiting
The NICHD Neonatal Research Network's Follow-Up study is a multi-center cohort in which surviving extremely low birth-weight infants born in participating network centers receive neurodevelopmental, neurosensory and functional assessments at 22-26 months corrected age (Infants born prior to July 1, 2012 were seen at 18-22 months corrected age). Data regarding pregnancy and neonatal outcome are collected prospectively. The goal is to identify potential maternal and neonatal risk factors that may... Read More
The NICHD Neonatal Research Network's Follow-Up study is a multi-center cohort in which surviving extremely low birth-weight infants born in participating network centers receive neurodevelopmental, neurosensory and functional assessments at 22-26 months corrected age (Infants born prior to July 1, 2012 were seen at 18-22 months corrected age). Data regarding pregnancy and neonatal outcome are collected prospectively. The goal is to identify potential maternal and neonatal risk factors that may affect infant neurodevelopment. Read Less
Gender:
ALL
Ages:
Between 18 months and 26 months
Trial Updated:
02/11/2025
Locations: Yale University, New Haven, Connecticut
Yale University, New Haven, Connecticut
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Generic Database of Very Low Birth Weight Infants
Recruiting
The Generic Database (GDB) is a registry of very low birth weight infants born alive in NICHD Neonatal Research Network (NRN) centers. The GDB collects observational baseline data on both mothers and infants, and the therapies used and outcomes of the infants. The information collected is not specific to a disease or treatment (i.e., it is "generic"). Data are analyzed to find associations and trends between baseline information, treatments, and infant outcome, and to develop future NRN trials.
The Generic Database (GDB) is a registry of very low birth weight infants born alive in NICHD Neonatal Research Network (NRN) centers. The GDB collects observational baseline data on both mothers and infants, and the therapies used and outcomes of the infants. The information collected is not specific to a disease or treatment (i.e., it is "generic"). Data are analyzed to find associations and trends between baseline information, treatments, and infant outcome, and to develop future NRN trials. Read Less
Gender:
ALL
Ages:
14 days and below
Trial Updated:
02/11/2025
Locations: Yale University, New Haven, Connecticut
Yale University, New Haven, Connecticut
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
TrialNet Pathway to Prevention of T1D
Recruiting
Rationale:
The accrual of data from the laboratory and from epidemiologic and prevention trials has improved the understanding of the etiology and pathogenesis of type 1 diabetes mellitus (T1DM). Genetic and immunologic factors play a key role in the development of T1DM, and characterization of the early metabolic abnormalities in T1DM is steadily increasing. However, information regarding the natural history of T1DM remains incomplete. The TrialNet Natural History Study of the Development of T... Read More
Rationale:
The accrual of data from the laboratory and from epidemiologic and prevention trials has improved the understanding of the etiology and pathogenesis of type 1 diabetes mellitus (T1DM). Genetic and immunologic factors play a key role in the development of T1DM, and characterization of the early metabolic abnormalities in T1DM is steadily increasing. However, information regarding the natural history of T1DM remains incomplete. The TrialNet Natural History Study of the Development of T1DM (Pathway to Prevention Study) has been designed to clarify this picture, and in so doing, will contribute to the development and implementation of studies aimed at prevention of and early treatment in T1DM.
Purpose:
TrialNet is an international network dedicated to the study, prevention, and early treatment of type 1 diabetes. TrialNet sites are located throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Sweden, Australia, and New Zealand. TrialNet is dedicated to testing new approaches to the prevention of and early intervention for type 1 diabetes.
The goal of the TrialNet Natural History Study of the Development of Type 1 Diabetes is to enhance our understanding of the demographic, immunologic, and metabolic characteristics of individuals at risk for developing type 1 diabetes.
The Natural History Study will screen relatives of people with type 1 diabetes to identify those at risk for developing the disease. Relatives of people with type 1 diabetes have about a 5% percent chance of being positive for the antibodies associated with diabetes. TrialNet will identify adults and children at risk for developing diabetes by testing for the presence of these antibodies in the blood. A positive antibody test is an early indication that damage to insulin-secreting cells may have begun. If this test is positive, additional testing will be offered to determine the likelihood that a person may develop diabetes. Individuals with antibodies will be offered the opportunity for further testing to determine their risk of developing diabetes over the next 5 years and to receive close monitoring for the development of diabetes. Read Less
Gender:
ALL
Ages:
Between 2 years and 45 years
Trial Updated:
06/30/2025
Locations: Yale University School of Medicine, New Haven, Connecticut
Yale University School of Medicine, New Haven, Connecticut
Conditions: Diabetes Mellitus, Type 1
Mucopolysaccharidosis I (MPS I) Registry
Recruiting
The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities.
The objectives of the Registry are:
* To evaluate the lon... Read More
The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities.
The objectives of the Registry are:
* To evaluate the long-term effectiveness and safety of Aldurazyme® (laronidase)
* To characterize and describe the MPS I population as a whole, including the variability, progression, and natural history of MPS I
* To help the MPS I medical community with the development of recommendations for monitoring patients and reports on patient outcomes to optimize patient care Read Less
Gender:
ALL
Ages:
All
Trial Updated:
11/19/2024
Locations: Yale - Site Number : 840047, New Haven, Connecticut
Yale - Site Number : 840047, New Haven, Connecticut
Conditions: Mucopolysaccharidosis I (MPS I)
Fabry Disease Registry & Pregnancy Sub-registry
Recruiting
The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.
The primary objectives of the Registry are:
* To enhance the understanding of the variability, progression, and natural history of F... Read More
The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.
The primary objectives of the Registry are:
* To enhance the understanding of the variability, progression, and natural history of Fabry disease, including heterozygous females with the disease;
* To assist the Fabry medical community with the development of recommendations for monitoring patients and reports on patient outcomes to help optimize patient care;
* To characterize and describe the Fabry population as a whole;
* To evaluate the long-term safety and effectiveness of Fabrazyme®
Fabry Pregnancy Sub-registry: This Sub-registry is a multicenter, international, longitudinal, observational, and voluntary program designed to track pregnancy outcomes for any pregnant woman enrolled in the Fabry Registry, regardless of whether she is receiving disease-specific therapy (such as enzyme replacement therapy with agalsidase beta) and irrespective of the commercial product with which she may be treated. Data from the Sub-registry are also used to fulfill various global regulatory requirements, to support product development/reimbursement, and for other research and non-research-related purposes. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician. If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
08/07/2025
Locations: Yale - Site Number : 840047, New Haven, Connecticut
Yale - Site Number : 840047, New Haven, Connecticut
Conditions: Fabry Disease
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
Recruiting
We, the researchers, are following the natural history of Albright hereditary osteodystrophy. We have found that growth hormone deficiency is very common in patients with pseudohypoparathyroidism type 1A, which falls under the broader condition termed Albright hereditary osteodystrophy. Patients with pseudohypoparathyroidism type 1A typically are short and obese. Some of these patients are not short during childhood, but due to a combination of factors, they end up short as adults. We are evalua... Read More
We, the researchers, are following the natural history of Albright hereditary osteodystrophy. We have found that growth hormone deficiency is very common in patients with pseudohypoparathyroidism type 1A, which falls under the broader condition termed Albright hereditary osteodystrophy. Patients with pseudohypoparathyroidism type 1A typically are short and obese. Some of these patients are not short during childhood, but due to a combination of factors, they end up short as adults. We are evaluating the effect of growth hormone treatment in those patients with pseudohypoparathyroidism type 1A who are found to be growth hormone deficient (under R01 FD002568, IND 67148, which ended); those who are growth hormone sufficient and were found to have a positive clinical response to growth hormone in a prior clinical trial (under R01 FD00FD003409, IND 67148, which ended); or those who meet the criteria of idiopathic short stature or SGA.
We are also evaluating neurocognitive and psychosocial functioning in participants with AHO in order to determine the specific impairments that are most common in the condition and to determine the best approach toward management.
Funding source -- Growth hormone study: FDA OOPD \[R01 FD003409 (which has ended) and R01 FD002568 (which has ended)\] Cognitive/behavior: NICHD R21 HD078864 (which has ended) Read Less
Gender:
ALL
Ages:
Between 2 months and 89 years
Trial Updated:
05/23/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Pseudohypoparathyroidism Type 1A, Albright Hereditary Osteodystrophy, Pseudopseudohypoparathyroidism
Pompe Disease Registry Protocol
Recruiting
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes.
The objectives of the Registry are:
* To enhance understanding of t... Read More
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes.
The objectives of the Registry are:
* To enhance understanding of the variability, progression, identification, and natural history of Pompe disease, with the ultimate goal of better guiding and assessing therapeutic intervention.
* To assist the Pompe medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care.
* To characterize the Pompe disease population.
* To evaluate the long-term effectiveness of alglucosidase alfa. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
08/06/2025
Locations: Yale - Site Number : 840047, New Haven, Connecticut
Yale - Site Number : 840047, New Haven, Connecticut
Conditions: Glycogen Storage Disease Type II, Pompe Disease
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Recruiting
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: Not set, Hartford, Connecticut +1 locations
Not set, Hartford, Connecticut
Not set, New Haven, Connecticut
Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
Recruiting
The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.
The objectives of the Registry are:
* To enhance understanding of the variability, progression, identification, and natural... Read More
The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.
The objectives of the Registry are:
* To enhance understanding of the variability, progression, identification, and natural history of Gaucher disease, with the ultimate goal of better guiding and assessing therapeutic intervention.
* To assist the Gaucher medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care.
* To characterize the Gaucher disease population.
* To evaluate the long-term effectiveness of imiglucerase and of eliglustat.
Gaucher Pregnancy Sub-registry: The primary objective of this Sub-registry is to track pregnancy outcomes, including complications and infant growth, in all women with Gaucher disease during pregnancy, regardless of whether they receive disease-specific therapy. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
08/12/2025
Locations: Yale - Site Number : 840047, New Haven, Connecticut
Yale - Site Number : 840047, New Haven, Connecticut
Conditions: Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Recruiting
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
07/22/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut +1 locations
Connecticut Children's Medical Center, Hartford, Connecticut
Yale University, New Haven, Connecticut
Conditions: Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
Paid Clinical Trials in Connecticut
Paid clinical trials offer volunteers a unique chance to contribute to medical progress while reaping valuable rewards – both monetary and non-monetary benefits. Those who participate can receive fair compensation that can help cover expenses or invest in their future.
With CT paid clinical trials, people get access to new treatments that have yet to hit the market. They provide valuable data for innovation. This is the kind of innovation that can take medical knowledge to new heights.
Clinical Trials For Health Volunteers in Connecticut
Every volunteer in a clinical trial is a catalyst for change. With health volunteers, such as yourself, research teams in Connecticut can test new medications, therapies, and other factors that can have a positive impact on healthcare.
Browse the list below to find trials that can suit your needs.
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Recruiting
The aim of the present study is to assess the availability of cannabinoid receptors (CB1R) in the human brain. CB1R are present in everyone's brain, regardless of whether or not someone has used cannabis. The investigators will image brain cannabinoid receptors using Positron Emission Tomography (PET) imaging and the radioligand OMAR, in healthy individuals and several conditions including 1) cannabis use disorders, 2) psychotic disorders, 3) prodrome of psychotic illness and 4) individuals with... Read More
The aim of the present study is to assess the availability of cannabinoid receptors (CB1R) in the human brain. CB1R are present in everyone's brain, regardless of whether or not someone has used cannabis. The investigators will image brain cannabinoid receptors using Positron Emission Tomography (PET) imaging and the radioligand OMAR, in healthy individuals and several conditions including 1) cannabis use disorders, 2) psychotic disorders, 3) prodrome of psychotic illness and 4) individuals with a family history of alcoholism, 5) Post-Traumatic Stress Disorder 6) Opioid Use Disorder using the PET imaging agent or radiotracer, \[11C\]OMAR. This will allow us to characterize the number and distribution of CB1R in these conditions. It is likely that the list of conditions will be expanded after the collection of pilot data and as new data on cannabinoids receptor function and psychiatric disorders becomes available.
Those in the cannabis us disorder arm of the study will have a PET scan on at least three occasions: once while smoking as usual, once after 48-hours of abstinence from cannabis, and a final time after 4 weeks of abstinence. Additional scans may be conducted within the 4 weeks and the last scan may be conducted well beyond 4 weeks. Similarly, while most schizophrenia patients may get scanned just once, a subgroup of patients may get scanned more than once. For example to tease out the effects of medications, unmedicated patients may get scanned while unmedicated and again after treatment with antipsychotic medications. Similarly prodromes may get scanned while in the prodromal stage off medications, on medications and after conversion to schizophrenia. Read Less
Gender:
MALE
Ages:
Between 18 years and 55 years
Trial Updated:
04/07/2025
Locations: Connecticut Mental Health Center, Clinical Neuroscience Research Unit, New Haven, Connecticut
Connecticut Mental Health Center, Clinical Neuroscience Research Unit, New Haven, Connecticut
Conditions: Schizophrenia, Cannabis Dependence, Prodromal for Psychotic Illness, Family History of Alcoholism, Healthy Control, Opioid-use Disorder, Post Traumatic Stress Disorder
SV2 PET Imaging With [11C]APP311
Recruiting
The aim of this study is to evaluate a new SV2A tracer, \[11C\]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.
The aim of this study is to evaluate a new SV2A tracer, \[11C\]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders. Read Less
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/31/2025
Locations: Conneticut Mental Health Center, New Haven, Connecticut
Conneticut Mental Health Center, New Haven, Connecticut
Conditions: Schizophrenia and Other Psychotic Disorders, Cannabis Use Disorder, Healthy
CBD-Microglia PET Study
Recruiting
This study aims to examine the effect of cannabidiol (CBD) pre-treatment on brain microglial activation in healthy human subjects. Secondarily, this study aims to examine the effect of cannabidiol (CBD) pre-treatment on central pain-sensitization in healthy human subjects.
This study aims to examine the effect of cannabidiol (CBD) pre-treatment on brain microglial activation in healthy human subjects. Secondarily, this study aims to examine the effect of cannabidiol (CBD) pre-treatment on central pain-sensitization in healthy human subjects. Read Less
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
07/15/2025
Locations: Connecticut Mental Health Center, New Haven, Connecticut
Connecticut Mental Health Center, New Haven, Connecticut
Conditions: CBD, Healthy
Aberrant Synaptic Plasticity in Cocaine Use Disorder: A 11C-UCB-J PET Study
Recruiting
The purpose of this research study is to measure synaptic density in the brain comparing individuals with cocaine use disorder to healthy controls.
The purpose of this research study is to measure synaptic density in the brain comparing individuals with cocaine use disorder to healthy controls. Read Less
Gender:
ALL
Ages:
Between 21 years and 60 years
Trial Updated:
10/29/2024
Locations: Connecticut Mental Health Center, New Haven, Connecticut
Connecticut Mental Health Center, New Haven, Connecticut
Conditions: Cocaine Use Disorder, Healthy Controls
In Vivo Study of THC-induced Immune-genome Changes at Single Cell Solution in HIV-infected Humans
Recruiting
In this study, the investigators hypothesize that THC alters the immunogenome in a cell type-specific fashion and alters cytokine production via epigenetic regulatory mechanisms and that these alterations differ between HIV-infected and HIV-uninfected host genomes.
In this study, the investigators hypothesize that THC alters the immunogenome in a cell type-specific fashion and alters cytokine production via epigenetic regulatory mechanisms and that these alterations differ between HIV-infected and HIV-uninfected host genomes. Read Less
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/31/2025
Locations: VA Connecticut Healthcare System, West Haven, Connecticut
VA Connecticut Healthcare System, West Haven, Connecticut
Conditions: HIV Infections, Healthy
SV2A Density Cannabis Use Disorder
Recruiting
The main purpose of this study is to determine whether hippocampal synaptic vesicle density estimated by hippocampal \[11C\]APP-311/\[11C\]UCB-J binding in individuals diagnosed with cannabis use disorder (CUDs) improves with at least 4 weeks of confirmed abstinence from cannabis, in comparison to healthy controls (HCs). Furthermore, any change in synaptic vesicle density will be placed in functional context by measuring verbal memory, which is sensitive to hippocampal function, before and after... Read More
The main purpose of this study is to determine whether hippocampal synaptic vesicle density estimated by hippocampal \[11C\]APP-311/\[11C\]UCB-J binding in individuals diagnosed with cannabis use disorder (CUDs) improves with at least 4 weeks of confirmed abstinence from cannabis, in comparison to healthy controls (HCs). Furthermore, any change in synaptic vesicle density will be placed in functional context by measuring verbal memory, which is sensitive to hippocampal function, before and after at least 4 weeks of confirmed abstinence. Finally, the relationship between hippocampal \[11C\]UCB-J binding in CUDs with measures of cannabis exposure (e.g., age of initiation, cumulative lifetime dose) will be explored. Read Less
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/29/2025
Locations: Yale University School of Medicine, New Haven, Connecticut
Yale University School of Medicine, New Haven, Connecticut
Conditions: Cannabis Use Disorder, Healthy
SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy
Recruiting
The purpose of this study is to longitudinally characterize and evaluate changes in synaptic density in the brain using novel positron-emission tomography (PET) scans; magnetic resonance imaging (MRI), and clinical laboratory markers associated with HIV-related injury in the central nervous system. This study will test hypotheses relating to the presence and mechanisms of aberrant brain structure at the synaptic level in living humans with virologically controlled HIV on antiretroviral therapy.... Read More
The purpose of this study is to longitudinally characterize and evaluate changes in synaptic density in the brain using novel positron-emission tomography (PET) scans; magnetic resonance imaging (MRI), and clinical laboratory markers associated with HIV-related injury in the central nervous system. This study will test hypotheses relating to the presence and mechanisms of aberrant brain structure at the synaptic level in living humans with virologically controlled HIV on antiretroviral therapy. To evaluate associations between PET imaging radiotracers \[11C\]UCB-J, a ligand for presynaptic vesicle protein 2A (SV2A), a vesicle membrane protein expressed in synapses, and PET \[11C\]PBR28 a measure of microglia function in the brain, the Yale PET center has developed an advanced approach of combining multiple distinct ligands in coordinated same-day PET imaging. Additionally, the study will evaluate the associations of this novel synaptic density marker with well-established clinical measures of neurocognitive performance and laboratory measures of blood and cerebrospinal fluid (CSF). Read Less
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
09/05/2024
Locations: Yale School of Medicne, Neuro ID Research Program, New Haven, Connecticut
Yale School of Medicne, Neuro ID Research Program, New Haven, Connecticut
Conditions: HIV Associated Neurocognitive Disorder, HIV Dementia, HIV Encephalitis, Healthy
OMAR Opioid Use Disorder
Recruiting
The goal of this research study is to examine the endocannabinoid (eCB) function in vivo in individuals with opioid use disorder (OUD) by measuring cannabinoid receptor 1 (CB1R) availability.
The goal of this research study is to examine the endocannabinoid (eCB) function in vivo in individuals with opioid use disorder (OUD) by measuring cannabinoid receptor 1 (CB1R) availability. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Connecticut Mental Health Center, Clinical Neuroscience Research Unit, New Haven, Connecticut
Connecticut Mental Health Center, Clinical Neuroscience Research Unit, New Haven, Connecticut
Conditions: Healthy Control, Opioid Use Disorder
PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects
Recruiting
The study will be conducted as an open-label and single-center study to evaluate the occupancy of ITI-1284 to the dopamine D2 receptor, serotonin 2A (5-HT2A) receptor, and serotonin transporter (SERT) in healthy subjects.
The study will be conducted as an open-label and single-center study to evaluate the occupancy of ITI-1284 to the dopamine D2 receptor, serotonin 2A (5-HT2A) receptor, and serotonin transporter (SERT) in healthy subjects. Read Less
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
01/24/2025
Locations: Clinical Site 1, New Haven, Connecticut
Clinical Site 1, New Haven, Connecticut
Conditions: Healthy Volunteers
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
Recruiting
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Yale-New Haven Hospital, New Haven, Connecticut
Yale-New Haven Hospital, New Haven, Connecticut
Conditions: Anemia, Sickle Cell, Healthy Volunteers
Medical Discoveries and Innovation in Connecticut
Connecticut has many dedicated healthcare professionals and research institutions that have made notable contributions to health and medicine. Here is a list of some of the discoveries the state is famous for.
- Discovery of Lyme Disease: In the 1970s, Dr. Allen Steere and his mentor Stephen Malawista discovered and named Lyme disease. At the time, Dr. Steere was working at Yale University in Connecticut. Since then, he has published about 300 scholarly articles on the infection.
- Advancements in Cardiovascular Surgery: Dr. William W. L. Glenn was a renowned heart surgeon. He invented a technique to treat congenital heart disease. He also participated in creating the early version of an artificial heart. From 1948 to 1975, he was the chief of heart surgery at Yale University.
- The First Artificial Heart: Dr. Robert K. Jarvik is a Connecticut-based physician who invented the first permanently implantable artificial heart. This groundbreaking medical device paved the way for future advancements in heart transplantation and cardiovascular care.
Why Connecticut Is A Great Place For Clinical Research
The Connecticut population is diverse, making it a great choice for clinical research. Data shows that 64.6% of its residents are White, 17.7% are Hispanic, 10.6% are Black, 4.9% are Asian, and 1.9% are Multiracial.